



**ImmuPharma PLC  
("ImmuPharma" or the "Company")**

**IMMUPHARMA AT BIO-EUROPE SPRING 2024  
18-20 March 2024 | Barcelona**

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Europe Spring. The event will be held between 18-20 March 2024, in Barcelona.

BIO-Europe Spring is the premier springtime partnering event, designed to provide biotechnology companies with the opportunity to present to and connect with investors together with the global biopharma community.

**Commenting on the event, Tim McCarthy, CEO of ImmuPharma said:** *"Following on from our recent announcements, including moving our lead asset P140 for SLE (Lupuzor™) forward, with our appointed CRO, Simbec-Orion, in parallel with our CIDP program, we are delighted to have BIO-Europe as the next key platform in 2024 to present our unique portfolio to key industry and investment specialists. Our focus will be to secure partnering opportunities across our programs including our P140 platform and our earlier stage but highly exciting anti-infective asset, BioAMB."*

For further information please contact:

<b>ImmuPharma PLC</b> ( <a href="http://www.immupharma.co.uk">www.immupharma.co.uk</a> )	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b> Neil Baldwin	+44 (0) 203 368 3550
<b>Stanford Capital Partners (Joint Broker)</b> Patrick Claridge, Bob Pountney	+44 (0) 203 650 3650
<b>SI Capital (Joint Broker)</b> Nick Emerson	+44 (0) 1483 413500

## Notes to Editors

### About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140/SLE (Lupuzor™), P140 "restores" the immune system back to normal, by enabling tolerogenic antigen presenting cells to function properly. **P140 is not an immunosuppressant unlike other molecules in development.** P140 is extremely safe, well-tolerated and patient friendly, and potentially can be self-administered through a subcutaneous injection, once a month for SLE.

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

### About BIO-Europe Spring, Barcelona, 2024

Connecting the global biopharma community to elevate life science partnerships.

BIO-Europe Spring, is the premier springtime partnering event, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings.

For more information go to: <https://informaconnect.com/bioeurope-spring/>

### About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.